Loading…
Loading…
The LMP Capital and Income Fund Inc. operates as a closed-end balanced mutual fund, primarily overseen by Legg Mason Partners Fund Advisor, LLC. Additional management responsibilities are shared with Clearbridge Investments, LLC, Western Asset Management Company Limited, and Western Asset Management Company. Its investment mandate extends globally, encompassing both public equity and fixed-income securities from businesses spanning various sectors. Key holdings include shares of large-capitalization firms, corporate bonds and notes of intermediate maturity with a minimum A- rating, both…
Is SCD's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital discharge versus comparator cohort No device-related adverse events (AEs) occurred in patients treated with QUELIMMUNE DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today new positive data from the late-breaking presentation at ASN Kidney Week 2026 in Denver, Colorado. The late-breaking poster, titled “Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics (SCD-PED) Surveillance Registry (SAVE) with a Historical Cohort,” compared survival in QUELIMMUNE (SCD-PED)-treated critically ill pediatric patients from its post-approval SAVE registry and one non-registry patient with life-threatening acute kidney injury (AKI) and sepsis requiring CRRT (QUELIMMUNE SCD-PED cohort) with clinically aligned cohorts from Kids' Inpatient Database (KID), the largest publicly available, all-payer pediatric inpatient care database in the United States representing broad clinical complexity.
Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (FDA) has granted SeaStar Medical Breakthrough Device Designation for its Selective Cytopheretic Device (SCD) therapy for the treatment of hyperinflammation in adult patients with sepsis or a septic condition. The Breakthrough Device Designation is a regulatory pathway designed to provide for accelerated development, assessment, and review for FDA approval of medical devices and potentially more effective treatments of life-threatening or irreversibly debilitating diseases or conditions.
Roche launches newborn screening test for three severe genetic conditionsPR NewswireBERLIN, Sept. 30, 2026This test expands Roche's early diagnostics portfolio
LMP Capital & Income Fund offers a 9.23% yield, emphasizing income and inflation protection via high allocations to MLPs and midstream energy equities. SCD's portfolio is differentiated by a 24.5% allocation to energy infrastructure, providing bond-like stability, inflation hedges, and higher yields than typical equity funds. Despite strong sector positioning, SCD underperformed the S&P 500 in recent months, but delivered a 9.16% total return, including distributions, over five months.
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% yield and nearly 5% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.